Worldwide Archives | PharmaShots

Roche Signs a Worldwide License Agreement with Parvus Therapeutics to Develop and Commercialize Navacim Platform for Autoimmune Diseases

May 17, 2019May 17, 2019Tuba Khan

Shots: Parvus to receive an upfront & milestones exceeding $800M and royalties on sales of products targeting for IBD, ALD & Celiac diseases, [...]

Novartis Acquires Worldwide Rights of Takeda’s Xiidra (lifitegrast ophthalmic solution) for $5.3B

May 9, 2019May 10, 2019Tuba Khan

Shots: Takeda to receive $3.4B upfront with 1.9B milestones, making a total deal value of $5.3B. Novartis to get WW rights of Xiidra [...]

Eisai Terminates its Worldwide Development & Commercialization Agreement with Purdue Pharma for Lemborexant

May 2, 2019May 6, 2019Tuba Khan

Shots: Purdue to receive one-time payment from Eisai, while releasing itself from rights to develop & commercialize lemborexant. Eisai acquires WW development and [...]

Fulcrum Therapeutics Signs an Exclusive Worldwide License Agreement with GSK to Develop and Commercialize Losmapimod for Facioscapulohumeral Muscular Dystrophy

April 24, 2019April 26, 2019Tuba Khan

Shots: GSK to receive shares of Fulcrum’s preferred stock, milestones & royalties on sales of losmapimod. Fulcrum to get exclusive WW rights to [...]

Bayer Exercises its Exclusive WW Option to License Vitrakvi & BAY 2731954 with Change-In-Control Clause from Loxo Oncology

February 18, 2019April 24, 2019Shiwani Sharma

Shots: With the acquisition of Loxo by Eli Lilly, Bayer exercises its option and get exclusive WW rights to develop and commercialize Vitrakvi [...]

Worldwide

Roche Signs a Worldwide License Agreement with Parvus Therapeutics to Develop and Commercialize Navacim Platform for Autoimmune Diseases

Novartis Acquires Worldwide Rights of Takeda’s Xiidra (lifitegrast ophthalmic solution) for $5.3B

Eisai Terminates its Worldwide Development & Commercialization Agreement with Purdue Pharma for Lemborexant

Fulcrum Therapeutics Signs an Exclusive Worldwide License Agreement with GSK to Develop and Commercialize Losmapimod for Facioscapulohumeral Muscular Dystrophy

CASI Pharmaceutical Signs an Exclusive Worldwide License Agreement with Black Belt for its TSK011010 Program

BeiGene Signs a Worldwide Co-Development and Commercialization Agreement with BioAtla for BA3071 and Tislelizumab

BeiGene and Ambrx Enters into a Worldwide Research and Development Collaboration to Develop Novel Biologics

ProMab Biotechnologies Signs Worldwide License Agreement with NantKwest to Develop Ab for Multiple Myeloma

Mustang Bio Signs an Exclusive Worldwide Collaboration with Nationwide Children’s Hospital for Glioblastoma Multiforme

Bayer Exercises its Exclusive WW Option to License Vitrakvi & BAY 2731954 with Change-In-Control Clause from Loxo Oncology